BRPI0515319A - análogos de quinolona - Google Patents

análogos de quinolona

Info

Publication number
BRPI0515319A
BRPI0515319A BRPI0515319-0A BRPI0515319A BRPI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A BR PI0515319 A BRPI0515319 A BR PI0515319A
Authority
BR
Brazil
Prior art keywords
quinolone
analogs
quinolone analogs
present
methods
Prior art date
Application number
BRPI0515319-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Jeffrey P Whitten
Fabrice Pierre
Collin Regan
Michael Schwaebe
George Petros Yiannikouros
Michael Jung
Peter Chua
Johnny Y Nagasawa
Original Assignee
Cylene Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US11/149,007 external-priority patent/US7652134B2/en
Application filed by Cylene Pharmaceuticals Inc filed Critical Cylene Pharmaceuticals Inc
Publication of BRPI0515319A publication Critical patent/BRPI0515319A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • C07D215/56Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D513/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/12Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D513/14Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0515319-0A 2004-09-17 2005-09-16 análogos de quinolona BRPI0515319A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US61103004P 2004-09-17 2004-09-17
US63860304P 2004-12-22 2004-12-22
US68898605P 2005-06-09 2005-06-09
US68879605P 2005-06-09 2005-06-09
US11/149,007 US7652134B2 (en) 2004-09-17 2005-06-09 Methods for converting quinolone esters into quinolone amides
PCT/US2005/033323 WO2006034113A2 (en) 2004-09-17 2005-09-16 Quinolone analogs as cell proliferation inhibitors

Publications (1)

Publication Number Publication Date
BRPI0515319A true BRPI0515319A (pt) 2008-07-22

Family

ID=35735203

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0515319-0A BRPI0515319A (pt) 2004-09-17 2005-09-16 análogos de quinolona

Country Status (11)

Country Link
US (1) US7816406B2 (https=)
EP (1) EP1802306A2 (https=)
JP (1) JP2008513485A (https=)
KR (1) KR100989029B1 (https=)
AU (1) AU2005286965B2 (https=)
BR (1) BRPI0515319A (https=)
CA (1) CA2580749C (https=)
IL (1) IL181857A0 (https=)
MX (1) MX2007003282A (https=)
NZ (1) NZ553746A (https=)
WO (1) WO2006034113A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928887B1 (en) 2005-08-05 2014-12-17 Senhwa Biosciences, Inc. Methods of preparing quinolone analogs
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
US7956064B2 (en) 2006-09-01 2011-06-07 Cylene Pharmaceuticals, Inc. Fused tricyclic compounds as serine-threonine protein kinase and PARP modulators
US20080318939A1 (en) * 2007-06-22 2008-12-25 Whitten Jeffrey P Methods for treating ophthalmic disorders
CN101801190A (zh) * 2007-06-22 2010-08-11 赛林药物股份有限公司 治疗异常细胞增殖性疾病的方法
WO2009097014A2 (en) * 2007-08-31 2009-08-06 Cylene Pharmaceuticals, Inc. Therapeutic kinase modulators
EP2201010B1 (en) 2007-09-14 2013-11-06 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
PL3092901T3 (pl) * 2007-10-05 2020-10-19 Senhwa Biosciences, Inc. Analogi chinolonu i sposoby z nimi związane
WO2011031745A1 (en) 2009-09-09 2011-03-17 Achaogen, Inc. Antibacterial fluoroquinolone analogs
RU2435758C1 (ru) * 2010-07-19 2011-12-10 Государственное образовательное учреждение высшего профессионального образования Волгоградский государственный технический университет (ВолгГТУ) Способ получения этилового эфира 3-оксо-3-(2,6-дихлорпиридин-3-ил) пропановой кислоты
US9758518B2 (en) 2015-03-04 2017-09-12 Pimera, Inc. Compositions, uses and methods for making them
PL3140305T3 (pl) 2014-05-09 2018-10-31 Pimera, Inc. Nowe kompozycje, ich zastosowania i sposoby wytwarzania
WO2016137471A1 (en) * 2015-02-26 2016-09-01 Nantpharma, Llc Method for enhanced heparin quality
WO2017087235A1 (en) 2015-11-20 2017-05-26 Senhwa Biosciences, Inc. Combination therapy of tetracyclic quinolone analogs for treating cancer
JP2018537486A (ja) * 2015-12-14 2018-12-20 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
CA3057741A1 (en) 2017-03-28 2018-10-04 Pimera, Inc. Novel crystal forms of a pol1 inhibitor
TWI884912B (zh) 2018-02-15 2025-06-01 生華生物科技股份有限公司 喹啉酮類似物及其鹽、組合物及其使用方法
JP2020189888A (ja) * 2020-08-28 2020-11-26 センワ バイオサイエンシズ インコーポレイテッド キノロン類似体及びその塩の結晶形
WO2025114459A1 (en) * 2023-11-28 2025-06-05 Genome Therapeutics Ltd Tetracyclic compounds for use in antibody-drug conjugates for the treatment of cancer
WO2025242908A2 (en) * 2024-05-24 2025-11-27 Genome Therapeutics Ltd Novel compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
DE3267485D1 (en) 1981-02-18 1986-01-02 Nippon Shinyaku Co Ltd Substituted carboxylic acid derivatives
ZA852769B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzothiazolo-quinoline antibacterial compounds
ZA852802B (en) * 1984-04-26 1985-11-27 Abbott Lab Benzoxazolo-quinoline antibacterial compounds
US4528285A (en) * 1984-04-26 1985-07-09 Abbott Laboratories Methylenedioxy quino-benzothiazine derivatives
WO1989012055A1 (fr) 1988-06-08 1989-12-14 Kyorin Pharmaceutical Co., Ltd. Agent antitumoral
US4959363A (en) * 1989-06-23 1990-09-25 Sterling Drug Inc. Quinolonecarboxamide compounds, their preparation and use as antivirals.
IE912902A1 (en) 1990-08-24 1992-02-26 Abbott Lab Quinbenzoxazine, quinobenzothiazine, and pyrido-acridine¹antineoplastic agents
JPH04117388A (ja) * 1990-09-07 1992-04-17 Hokuriku Seiyaku Co Ltd チアゾロキノリン―4―カルボン酸誘導体
US5646163A (en) * 1992-10-30 1997-07-08 The Procter & Gamble Company Quinolone 5-(N-heterosubstituted amino) antimicrobials
GB9402275D0 (en) * 1994-02-07 1994-03-30 Fujisawa Pharmaceutical Co Quinoline derivatives
US6559145B2 (en) * 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
US6699989B1 (en) 2000-08-28 2004-03-02 B. Vithal Shetty Antiviral and antimicrobial guanidine or biguanidine derivatives
DE60113450T2 (de) * 2000-12-14 2006-07-13 The Procter & Gamble Company, Cincinnati Antimikrobielle chinolone
US6821969B2 (en) * 2001-02-13 2004-11-23 Pharmacia & Upjohn Company Thioxazinoquinolones as antiviral agents
US6900224B2 (en) 2002-07-31 2005-05-31 The Procter & Gamble Company Antimicrobial quinolones, their compositions and uses
EP1610759A4 (en) 2003-04-07 2007-04-25 Cylene Pharmaceuticals Inc SUBSTITUTED CHINOBENZOXAZINE ANALOGUE
CN104324029A (zh) * 2004-03-15 2015-02-04 逊尼希思制药公司 Sns-595及其使用方法

Also Published As

Publication number Publication date
MX2007003282A (es) 2007-10-16
JP2008513485A (ja) 2008-05-01
AU2005286965A1 (en) 2006-03-30
AU2005286965B2 (en) 2009-10-22
US20060074089A1 (en) 2006-04-06
IL181857A0 (en) 2007-07-04
US7816406B2 (en) 2010-10-19
CA2580749C (en) 2014-01-28
KR20070085264A (ko) 2007-08-27
CA2580749A1 (en) 2006-03-30
KR100989029B1 (ko) 2010-10-25
WO2006034113A3 (en) 2006-08-24
WO2006034113A2 (en) 2006-03-30
EP1802306A2 (en) 2007-07-04
NZ553746A (en) 2010-06-25

Similar Documents

Publication Publication Date Title
BRPI0515319A (pt) análogos de quinolona
NL301145I2 (nl) Tirbanibulin
BR112012008385A2 (pt) inibidores de p13 cinase e uso dos mesmos.
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
MX2009008347A (es) Oxabicicloheptanos y oxabicicloheptenos, su preparacion y uso.
ECSP099027A (es) Anticuerpos anti-dll4 y métodos que los usan
ECSP088543A (es) Anticuerpos anti-ox40l y métodos que los utilizan
BR112013008140A2 (pt) "compostos imidazotriazinona".
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
BRPI0710521A2 (pt) quinazolinas para inibição de pdk1
CR9786A (es) Compuestos de bencimidazol-tiofeno
DK1934174T3 (da) Azetidiner som MEK inhibitorer til behandling af proliferative sygdomme
UA95768C2 (ru) Антагонисты мускариновых рецепторов ацетилхолина
BRPI0811635A2 (pt) Compostos de arilazol-2-il cianoetilamino, métodos para fazê-los e métodos para o uso dos mesmos
ECSP099378A (es) Compuestos y composiciones como inhibidores de la proteina quinasa
EA200701192A1 (ru) Антагонисты toll-подобного рецептора 3, способы их получения и применение
BRPI0615270A2 (pt) pirazol fundido como inibidores de p38 map cinase
NO20072179L (no) Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer
IL176142A0 (en) Processes for preparing montelukast sodium
ECSP088743A (es) Anticuerpos para egfl7 y métodos para su uso
SV2006002232A (es) Inhibidores bace ref. x-16940
TW200731974A (en) Transdermal system for verenicline
WO2007146813A3 (en) Pyridinone analogs as cell proliferation inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014.